BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (NASDAQ:HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will present at the at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference in New York, New York on Monday, November 6, 2023 at 3:10 p.m. EST and at the Stifel Healthcare Conference in New York, New York, on Tuesday, November 14, 2023 at 11:30 a.m. EST. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.
Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference
Fireside chat details: |
|
Date: | Monday, November 6, 2023 |
Time: | 3:10 – 3:40 p.m. Eastern Standard Time (EST) |
Moderator: | Seamus Fernandez |
Location: | JW Marriott Essex House, New York, New York |
HilleVax Participant: | Robert Hershberg, MD, PhD, Chairman and Chief Executive Officer |
Webcast & Audit Visual: | https://guggenheim.metameetings.net/events/ini23/sessions/48816-hillevax-inc-hlvx/webcast?gpu_only=true&kiosk=true |
Stifel Global Healthcare Conference